A Phase 3 interventional study of pregabalin in Diabetic Neuropathy, Painful, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 27 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pregabalin in Diabetic Neuropathies — 1 open to participants now, 1 under way, 1 of them phase 3. Pregabalin · Diabetic Neuropathies.
Among the 17 studies testing pregabalin in Diabetic Neuropathies, this one is the 14th largest by enrollment, is the only one that started in 2008, is one of 10 in phase 3, and was the 7th registered.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
Browse Diabetic Neuropathies studies →1 of the 17 studies testing pregabalin in Diabetic Neuropathies is open now, in 1 country. Recruiting first, the newest first:
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Median enrollment 241 across the 17 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
12 studies in Diabetic Neuropathies by Viatris Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 5 (42%) have results posted.
Among the 12 studies in Diabetic Neuropathies by Viatris Inc., this one is the 11th largest by enrollment, is the only one that started in 2008, is one of 8 in phase 3, and was the 6th registered.
Viatris Inc.’s Diabetic Neuropathies studies by the year they started, since 1998.
1 of the studies testing pregabalin in Diabetic Neuropathies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing pregabalin in Diabetic Neuropathies, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 12 in Diabetic Neuropathies:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of the long-term use of pregabalin at doses up to 600 mg/day in patients with painful diabetic peripheral neuropathy who have completed 13 weeks of dosing in Study A0081163
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pregabalin
Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Summary of Adverse Events
Number of participants with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Participants are counted only once per treatment in each row.
Time frame: 53 weeks
Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.
Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)
Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.
Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)
Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.
Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)
Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.
Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)
Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.
Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)
Thirty-six (36) centers in Japan
| Milestone | Pregabalin |
|---|---|
| Started | 123 |
| Completed | 97 |
| Not completed | 26 |
| Withdrew: Adverse event | 19 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Physician decision | 1 |
Number of participants with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Participants are counted only once per treatment in each row.
| participants | Pregabalin |
|---|---|
| Participants with adverse events | 114 |
| Participants with serious adverse events | 21 |
| Participants with severe adverse events | 7 |
| Participants discontinued due to adverse events | 17 |
| Dose reduced or temporary discontinuation | 43 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.
| score on scale | Pregabalin |
|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores | -3.5 ± 5.1 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.
| score on scale | Pregabalin |
|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores | -1.2 ± 2.4 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.
| score on scale | Pregabalin |
|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores | -4.7 ± 6.8 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.
| mm | Pregabalin |
|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores | -25.4 ± 26.4 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.
| score on scale | Pregabalin |
|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores | -0.7 ± 1.1 |
Collected over 53 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 21/123 (17.1%) | 101/123 (82.1%) |
| Event | Pregabalin |
|---|---|
| PneumoniaInfections and infestations | 3/123 |
| CellulitisInfections and infestations | 2/123 |
| Cerebral infarctionNervous system disorders | 2/123 |
| Atrioventricular block completeCardiac disorders | 1/123 |
| Meniere's diseaseEar and labyrinth disorders | 1/123 |
| Diabetic gangreneInfections and infestations | 1/123 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/123 |
| Femur fractureInjury, poisoning and procedural complications | 1/123 |
| Hand fractureInjury, poisoning and procedural complications | 1/123 |
| Thermal burnInjury, poisoning and procedural complications | 1/123 |
| Event | Pregabalin |
|---|---|
| NasopharyngitisInfections and infestations | 39/123 |
| Weight increasedInvestigations | 35/123 |
| SomnolenceNervous system disorders | 30/123 |
| DizzinessNervous system disorders | 29/123 |
| Oedema peripheralGeneral disorders | 21/123 |
| FallInjury, poisoning and procedural complications | 14/123 |
| ConstipationGastrointestinal disorders | 11/123 |
| Face oedemaGeneral disorders | 10/123 |
| EczemaSkin and subcutaneous tissue disorders | 10/123 |
| Diabetic retinopathyEye disorders | 9/123 |
| Age, Customized(participants) | Pregabalin |
|---|---|
| < 18 years | 0 |
| 18 - 44 years | 6 |
| 45 - 64 years | 71 |
| >= 65 years | 46 |
| Age, Customized(years) | Pregabalin |
|---|---|
| Mean | 61.7 ± 10.0 |
| Sex: Female, Male(Participants) | Pregabalin |
|---|---|
| Female | 23 |
| Male | 100 |
The record gives a start of Feb 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →